Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-Current Assets (2016 - 2026)

Ptc Therapeutics has reported Non-Current Assets over the past 14 years, most recently at $624.8 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 84.04% year-over-year to $624.8 million; the TTM value through Dec 2025 reached $2.0 billion, down 5.7%, while the annual FY2025 figure was $624.8 million, 84.04% up from the prior year.
  • Non-Current Assets for Q4 2025 was $624.8 million at Ptc Therapeutics, down from $635.9 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $1.1 billion in Q2 2022 and troughed at $339.0 million in Q1 2025.
  • A 5-year average of $767.4 million and a median of $734.0 million in 2023 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: crashed 49.86% in 2024 and later surged 84.04% in 2025.
  • Year by year, Non-Current Assets stood at $983.7 million in 2021, then grew by 2.86% to $1.0 billion in 2022, then plummeted by 33.08% to $677.1 million in 2023, then crashed by 49.86% to $339.5 million in 2024, then soared by 84.04% to $624.8 million in 2025.
  • Business Quant data shows Non-Current Assets for PTCT at $624.8 million in Q4 2025, $635.9 million in Q3 2025, and $361.3 million in Q2 2025.